ENTA

Enanta Pharmaceuticals Inc

10.71

Oct 30 • 3:59 PM ET -0.44 (-3.95%)

10.71

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: AVIR CLDX ASMB KYMR VIR IVVD JSPR COCP ABUS ALGS

| Held by: VTI IWM VXF IBB VTWO IWN DFAS SCHA IWO IWC

Scroll to Statements

Index	RUT
Market Cap	311.93M
Enterprise Value	304.46M
Income	-63.23M
Sales	65.26M
Book/sh	3.47
Cash/sh	6.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	120
IPO	Mar 21, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	4.78
P/B	3.09
P/C	1.65
P/FCF	-
EV/EBITDA	-
EV/Sales	4.67
Quick Ratio	3.76
Current Ratio	3.76
Debt/Eq	1.80
LT Debt/Eq	1.40
Option/Short	Yes / Yes

EPS (ttm)	-2.41
EPS next Y	-2.20
EPS next Q	-0.72
EPS this Y	40.29%
EPS next Y	4.13%
EPS next 5Y	11.43%
EPS past 3/5Y	13.40% -16.17%
Sales past 3/5Y	-8.82% -11.81%
EPS Y/Y TTM	44.24%
Sales Y/Y TTM	0.70%
EPS Q/Q	21.50%
Sales Q/Q	-21.60%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-31.50% -14.34%

Insider Own	4.74%
Insider Trans	0.00%
Inst Own	94.12%
Inst Trans	3.71%
ROA	-21.15%
ROE	-70.12%
ROIC	-26.08%
Gross Margin	92.48%
Oper. Margin	-89.99%
Profit Margin	-96.89%
SMA20	-8.68%
SMA50	-14.54%
SMA200	-18.83%
Trades

Shs Outstand	29.12M
Shs Float	27.75M
Short Float	8.16%
Short Ratio	9.21
Short Interest	2.27M
52W High	17.15 -37.55%
52W Low	10.22 4.79%
Volatility	6.19% 5.50%
ATR (14)	0.66
RSI (14)	36.65
Beta	0.73
Rel Volume	0.82
Avg Volume	245.93K
Volume	202,346

Perf Week	-7.99%
Perf Month	-16.59%
Perf Quarter	-17.30%
Perf Half Y	-25.37%
Perf YTD	-32.09%
Perf Year	-1.38%
Perf 3Y	21.43%
Perf 5Y	-87.52%
Perf 10Y	-55.24%
Recom	1.17
Target Price	21.83
Prev Close	11.15
Price	10.71
Change %	-3.95%

Consensus

Strong Buy

Avg. Price Target

$21.83

Implied Upside

+103.8%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 26, 2026	Initiated	RRodman & Renshaw	Buy	$20	+86.7%
Nov 14, 2025	Initiated	JJP Morgan	Overweight
Oct 01, 2025	Upgrade	JJefferies	Hold → Buy	$20	+86.7%
Jul 28, 2025	Resumed	HH.C. Wainwright	Buy	$20	+86.7%
Aug 09, 2023	Downgrade	JJP Morgan	Neutral → Underweight	$14	+30.7%
Aug 08, 2023	Downgrade	JJefferies	Buy → Hold	$49 → $18	+68.1%
Dec 09, 2022	Initiated	HH.C. Wainwright	Buy	$56	+422.9%
Jul 06, 2022	Upgrade	EEvercore ISI	In-line → Outperform	$62	+478.9%
Jun 01, 2022	Upgrade	EEvercore ISI	Underperform → In-line	$39	+264.1%
Oct 07, 2021	Initiated	JJefferies	Buy	$95	+787.0%
Sep 09, 2021	Initiated	SSVB Leerink	Mkt Perform	$55	+413.5%
Jan 29, 2021	Upgrade	JJP Morgan	Underweight → Neutral	$55	+413.5%
Nov 24, 2020	Initiated	EEvercore ISI	Underperform	$30	+180.1%
Aug 28, 2020	Resumed	RROTH Capital	Buy	$104	+871.1%
Aug 26, 2020	Initiated	PPiper Sandler	Overweight	$87	+712.3%
Jul 27, 2020	Upgrade	JJMP Securities	Mkt Perform → Mkt Outperform	$70	+553.6%
Mar 17, 2020	Upgrade	RRobert W. Baird	Neutral → Outperform	$60	+460.2%
Nov 22, 2019	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Sep 26, 2019	Downgrade	JJP Morgan	Neutral → Underweight	$86 → $57	+432.2%
May 24, 2019	Initiated	WWolfe Research	Outperform	$117	+992.4%

Oct-28-26 07:00AM	Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership (Business Wire) -5.17%
Oct-26-26 07:00AM	Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) (Business Wire)
Oct-13-26 07:00AM	Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek 2026 (Business Wire) -6.34%
Sep-01-26 07:00AM	Enanta Pharmaceuticals to Participate in September Investor Conferences (Business Wire)
Aug-10-26 04:06PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 (Business Wire)
Jun-23-26 05:10AM	Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus (Business Wire) +5.16%
Jun-18-26 07:00AM	Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) (Business Wire)
May-28-26 07:00AM	Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-11-26 04:07PM	Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot (Associated Press) -6.02%
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 (Business Wire)
11:45AM	Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? (Quartz)
May-04-26 07:00AM	Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 (Business Wire)
Apr-13-26 07:00AM	Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria (Business Wire)
Apr-07-26 07:00AM	Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 (Business Wire)
07:00AM	Loading…
Mar-30-26 07:00AM	Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) (Business Wire)
Mar-03-26 07:00AM	Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference (Business Wire)
Feb-12-26 12:00PM	What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock (Zacks)
Feb-10-26 07:00AM	Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting (Business Wire)
Feb-09-26 05:05PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 (Business Wire)
Jan-15-26 05:39PM	JPM26: Enanta outlines strategy to lead in RSV therapeutics (Pharmaceutical Technology) -5.54%
Jan-08-26 07:00AM	Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook (Business Wire)
Jan-05-26 07:00AM	Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-26-25 08:42AM	Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? (Zacks)
Dec-22-25 09:17AM	Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? (Zacks) +5.33%
Nov-21-25 09:55AM	Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade (Zacks)
Nov-17-25 04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 (Business Wire) +6.30%
Nov-04-25 07:00AM	Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Loading…
Oct-20-25 07:00AM	Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 (Business Wire)
Oct-16-25 04:33PM	Enanta's Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults (Insider Monkey)
Oct-07-25 07:00AM	Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 (Business Wire)
Oct-02-25 04:01PM	Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive) -11.36%
Sep-30-25 09:00PM	Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) -21.04%
04:11PM	Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
06:58AM	Enanta stock doubles despite RSV trial missing primary endpoint (Clinical Trials Arena)
Sep-29-25 01:28PM	Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults (Benzinga) +91.90%
06:30AM	Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults (Business Wire)
06:07AM	Premarket movers: Merus, GSK, Novo Nordisk (MarketWatch)
Sep-26-25 04:01PM	Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults (Business Wire)
Sep-03-25 10:46AM	Enanta CFO dies after taking medical leave of absence (CFO Dive)
06:00AM	Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. (Business Wire)
Aug-21-25 07:00AM	Enanta Pharmaceuticals to Participate in September Investor Conferences (Business Wire)
Aug-20-25 12:53PM	Pfizer battles another Paxlovid lawsuit from Enanta (Pharmaceutical Technology) +5.13%
07:00AM	Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union (Business Wire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.94% +5.70%
06:07PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 (Business Wire)
Aug-05-25 07:00AM	Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series (Business Wire)
Jul-30-25 10:00AM	Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth (Zacks) -6.05%
Jul-15-25 07:00AM	Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series (Business Wire) -5.32%
Jun-11-25 12:34PM	Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus (Business Wire)
May-27-25 07:00AM	Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-22-25 07:00AM	Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting (Business Wire)
May-15-25 09:55AM	Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? (Zacks)
May-12-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.31% -5.77%
04:10PM	Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Business Wire)
May-08-25 06:20PM	Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.14%
May-05-25 05:53PM	Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts (Insider Monkey) -8.57% -7.17%
Apr-30-25 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.18%
Apr-08-25 07:00AM	Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 (Business Wire)
Mar-17-25 07:00AM	Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Business Wire) -8.27%
Mar-12-25 07:00AM	Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium (Business Wire)
Feb-14-25 12:00PM	Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Feb-10-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.08%
04:11PM	Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 (Business Wire)
Jan-30-25 08:03AM	Shionogis RSV antiviral reduces viral load in Phase II human challenge trial (Clinical Trials Arena)
Jan-08-25 07:00AM	Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-24 07:00AM	Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit (Business Wire)
Dec-23-24 09:43AM	Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? (Zacks)
Dec-10-24 12:34PM	Enantas zelicapavir shows promise in paediatric respiratory syncytial virus trial (Clinical Trials Arena)
Dec-09-24 06:30AM	Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) (Business Wire) +11.75%
Dec-06-24 05:00PM	Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) (Business Wire)
Nov-29-24 01:00AM	Enanta Pharmaceuticals Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility (TipRanks)
Nov-25-24 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 (Business Wire)
Oct-19-24 11:13AM	Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline (Insider Monkey)
Oct-17-24 07:02PM	Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares (GuruFocus.com)
Oct-02-24 07:53AM	Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Sep-27-24 06:45AM	J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers (BioPharma Dive)
Sep-26-24 06:00AM	Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) (Business Wire)
Sep-03-24 07:00AM	Enanta Pharmaceuticals to Participate in Investor Conferences in September (Business Wire)
Aug-09-24 07:27AM	Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners Top Holding Right Now? (Insider Monkey) -6.75%
Aug-05-24 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.55%
04:09PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter (Business Wire)
Jul-15-24 10:10AM	Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock? (Zacks)
May-29-24 07:00AM	Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference (Business Wire)
May-07-24 11:43AM	JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating (MT Newswires) -10.27%
10:24AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript (Insider Monkey)
07:10AM	Q2 2024 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference (Business Wire)
03:07AM	Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-06-24 08:59PM	ENTA Stock Earnings: Enanta Pharma Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:47PM	Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Capps Kathleen S.	See Remarks	Dec 05 '25	Sale	14.23	323	4,596	8,377	Dec 05 06:53 PM
Trout Harry R. III	See Remarks	Dec 05 '25	Sale	14.23	542	7,713	16,348	Dec 05 06:47 PM
Rottinghaus Scott T.	Chief Medical Officer	Dec 05 '25	Sale	14.23	798	11,356	21,792	Dec 05 06:46 PM
Luu Brendan	Chief Business Officer	Dec 05 '25	Sale	14.23	1,394	19,837	38,329	Dec 05 06:45 PM
Kieffer Tara Lynn	Chief Product Strategy Officer	Dec 05 '25	Sale	14.23	2,106	29,968	30,620	Dec 05 06:44 PM
Or Yat Sun	Chief Scientific Officer	Dec 05 '25	Sale	14.23	2,390	34,010	371,392	Dec 05 06:43 PM
Luly Jay R.	President and CEO	Dec 05 '25	Sale	14.23	4,743	67,493	858,026	Dec 05 06:41 PM
Luly Jay R.	Officer	Dec 05 '25	Proposed Sale	14.24	4,743	67,540		Dec 05 06:38 PM
Capps Kathleen S.	See Remarks	Dec 02 '25	Sale	13.96	207	2,890	8,700	Dec 03 05:09 PM
Trout Harry R. III	See Remarks	Dec 02 '25	Sale	13.96	380	5,305	16,890	Dec 03 05:05 PM

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

PresidentDr. Jay R. Luly Ph.D.

Chief Scientific OfficerDr. Yat Sun Or Ph.D.

Chief Medical OfficerDr. Scott T. Rottinghaus M.D.

VP of Finance & Interim Principal Financial OfficerMr. Harry R. Trout III

Executive Director of AccountingMs. Kathleen S. Capps CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTA

Enanta Pharmaceuticals Inc

Upgrade your Finviz experience